Supplemental figure S1: Patient derived primary CD38 high myeloma cells display skewed expression of intracellular kappa-or lambda-light chain. Cells obtained from bone marrow aspirates of patients with myeloma (n=8) or plasma cell leukemia (PCL; n=1) were stained for surface CD38 and for intracellular kappa-and lambda-light chains and were analyzed by flowcytometry. Dotplots show representative data from one myeloma patient. Expression of intracellular kappa-and lambda-light chains is depicted for the CD38 high subset. Supplemental figure S2: Gating strategy for CD107a degranulation assay. Myeloma cell lines or K562 were co-cultured with NK cells isolated from peripheral blood in the presence of anti-CD107a (row A,C,D) or an isotype control (row B) at 21% of oxygen. After 12 hours, cells were stained for KIR and NKG2A, and degranulation (CD107a+) was measured by flow cytometry. For analysis, NK cells (CD3-CD56+) were subdivided into 16 subpopulations based on their expression of different inhibitory receptors. The percentage of CD107a+ cells in each of the 16 subsets was analyzed. Dotplots show data for the subsets expressing only one of the inhibitory receptors; i.e. single positive for NKG2A, KIR2DL1, KIR2DL2/3 or KIR3DL1 upon co-culture with U266 or the positive control cell line K562.

